Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAMTA TARAK CHOKSI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1780644351
CMS profile
35710
Location
TRINITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$4,018.95

195 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,819.01 193
Education $199.94 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAMTA TARAK CHOKSI

NPI 1780644351 · CMS profile ID 35710

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TRINITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780644351?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAMTA TARAK CHOKSI, NPI 1780644351, CMS profile ID 35710. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780644351?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MAMTA TARAK CHOKSI, NPI 1780644351, CMS profile ID 35710. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780644351?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MAMTA TARAK CHOKSI, NPI 1780644351, CMS profile ID 35710, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780644351?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

195 matching records · $4,018.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 195 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 195.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $29.8906/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212890282 CMS
GlaxoSmithKline, LLC. $19.1206/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190465346 CMS
GlaxoSmithKline, LLC. $21.0106/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191827348 CMS
Regeneron Healthcare Solutions, Inc. $19.8306/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212890280 CMS
PFIZER INC. $16.2805/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231730508 CMS
PFIZER INC. $18.1305/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228881897 CMS
E.R. Squibb & Sons, L.L.C. $19.3405/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532721 CMS
Novartis Pharmaceuticals Corporation $13.3305/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200084910 CMS
Novartis Pharmaceuticals Corporation $0.2805/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200084912 CMS
TerSera Therapeutics LLC $39.6805/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244059352 CMS
E.R. Squibb & Sons, L.L.C. $19.3805/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532719 CMS
Lilly USA, LLC $32.1505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186816875 CMS
Agios Pharmaceuticals, Inc. $27.8005/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253253958 CMS
Merck Sharp & Dohme LLC $23.4805/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238310036 CMS
Celgene Corporation $20.5905/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532729 CMS
Celgene Corporation $13.5105/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532725 CMS
Celgene Corporation $28.5205/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532715 CMS
Celgene Corporation $16.2705/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532727 CMS
E.R. Squibb & Sons, L.L.C. $23.4905/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532767 CMS
Legend Biotech USA Inc. $26.2405/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236482552 CMS
Celgene Corporation $5.5004/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532713 CMS
Celgene Corporation $7.7204/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532723 CMS
Celgene Corporation $9.9104/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532889 CMS
Celgene Corporation $5.5104/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532891 CMS
Novartis Pharmaceuticals Corporation $25.5804/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200084904 CMS
Kite Pharma, Inc. $24.3104/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212084539 CMS
Merck Sharp & Dohme LLC $26.0704/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238138099 CMS
SERVIER PHARMACEUTICALS LLC $19.7804/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229104588 CMS
PFIZER INC. $16.9904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228845790 CMS
Celgene Corporation $21.2804/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532907 CMS
E.R. Squibb & Sons, L.L.C. $4.5504/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532885 CMS
Gilead Sciences, Inc. $19.2704/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234535994 CMS
Incyte Corporation $24.0104/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226108707 CMS
Novartis Pharmaceuticals Corporation $26.5504/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200084898 CMS
GENZYME CORPORATION $25.3004/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233377536 CMS
PFIZER INC. $17.9904/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228862447 CMS
Novartis Pharmaceuticals Corporation $11.4404/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200084902 CMS
Lilly USA, LLC $25.4104/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186828694 CMS
RECORDATI_RARE_DISEASES_INC. $14.4204/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181713956 CMS
Regeneron Healthcare Solutions, Inc. $25.0504/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212890278 CMS
Janssen Biotech, Inc. $23.8804/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175322229 CMS
Celgene Corporation $29.7304/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532873 CMS
Celgene Corporation $14.8804/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532893 CMS
Janssen Biotech, Inc. $18.8104/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175323695 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.7304/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225495829 CMS
E.R. Squibb & Sons, L.L.C. $14.1204/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532879 CMS
BeOne Medicines USA, Inc. $31.1704/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202889782 CMS
TerSera Therapeutics LLC $24.9704/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244059350 CMS
Celgene Corporation $18.7503/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184532897 CMS
Daiichi Sankyo Inc. $23.7503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197051823 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,121.19 215
PY2020 $3,209.70 111
PY2021 $3,643.66 114
PY2022 $2,549.76 160
PY2023 $11,247.75 189
PY2024 $3,024.92 162
PY2025 $4,018.95 195

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $323,504.95 54

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739049
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175321491
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175321604
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175324234
Principal investigator 1 Janssen Research & Development, LLC $234.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175320078
Principal investigator 1 Janssen Research & Development, LLC $47.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325290
Principal investigator 1 Janssen Research & Development, LLC $2,600.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175319833
Principal investigator 1 Janssen Research & Development, LLC $4,022.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325919
Principal investigator 1 Janssen Research & Development, LLC $562.50 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325508
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325827
Principal investigator 1 Janssen Research & Development, LLC $14,686.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325635
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739047
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175322863
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175321829
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739045
Principal investigator 1 Janssen Research & Development, LLC $33,500.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175320290
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175321876
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324843
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738995
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 09/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175319097
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738997
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,900.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738999
Principal investigator 1 Janssen Research & Development, LLC $4,200.00 08/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175321914
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175326060
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739001
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175319938
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175321213
Principal investigator 1 Janssen Research & Development, LLC $33,500.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324153
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739003
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $94,951.84 06/25/2025 Non-covered Recipient Entity
Florida Cancer Specialists - North
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235997351
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,318.75 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185544785
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739005
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739007
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739009
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739011
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,080.03 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739013
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.56 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739015
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $403.99 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739017
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $145.80 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739019
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $58.73 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739021
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,012.50 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739023
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $202.50 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739025
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,947.04 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739027
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,947.04 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739029
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,947.04 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739031
Principal investigator 1 AstraZeneca Pharmaceuticals LP $51,108.63 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185544783
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,297.11 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185544789
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739033
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739035
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,125.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739037
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739039
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739041
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,056.89 02/25/2025 Non-covered Recipient Entity
Florida Cancer Specialists - North
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235997353
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233739043